Document Detail

Antifungal activity of azole compounds CPA18 and CPA109 against azole-susceptible and -resistant strains of Candida albicans.
MedLine Citation:
PMID:  23292344     Owner:  NLM     Status:  Publisher    
OBJECTIVES: In this study we investigated the in vitro fungistatic and fungicidal activities of CPA18 and CPA109, two azole compounds with original structural features, alone and in combination with fluconazole against fluconazole-susceptible and -resistant Candida albicans strains. METHODS: Antifungal activities were measured by MIC evaluation and time-kill studies. Azole binding analysis was performed by UV-Vis spectroscopy. Hyphal growth inhibition and filipin and propidium iodide staining assays were used for morphological analysis. An analysis of membrane lipids was also performed to gauge alterations in membrane composition and integrity. Synergism was calculated using fractional inhibitory concentration indices (FICIs). Evaluation of cytotoxicity towards murine macrophages was performed to verify selective antifungal activity. RESULTS: Even though their binding affinity to C. albicans Erg11p is comparable to that of fluconazole, CPA compounds are active against resistant strains of C. albicans with a mutation in ERG11 sequences and/or overexpressing the ABC transporter genes CDR1 and CDR2, which encode ATP-dependent efflux pumps. Moreover, CPA18 is fungistatic, even against the two resistant strains, and was found to be synergistic with fluconazole. Differently from fluconazole and other related azoles, CPA compounds induced marked changes in membrane permeability and dramatic alterations in membrane lipid composition. CONCLUSIONS: Our outcomes suggest that CPA compounds are able to overcome major mechanisms of resistance in C. albicans. Also, they are promising candidates for combination treatment that could reduce the toxicity caused by high fluconazole doses, particularly in immunocompromised patients.
Elena C Calabrese; Sabrina Castellano; Marisabella Santoriello; Cristina Sgherri; Mike F Quartacci; Lucia Calucci; Andrew G S Warrilow; David C Lamb; Steven L Kelly; Ciro Milite; Ilaria Granata; Gianluca Sbardella; Giorgio Stefancich; Bruno Maresca; Amalia Porta
Related Documents :
8150954 - Evaluation of differential inoculum disk diffusion method and vitek gps-sa card for det...
4874454 - Identification of micrococcaceae in clinical bacteriology.
21230304 - Viscoplasticity and large-scale chain relaxation in glassy-polymeric strain hardening.
4979104 - Inhibition of fibrinogen reaction by polysaccharide of encapsulated staphylococcus aureus.
14982804 - In vitro activities of new quinolones and oxazolidinones against actinomadura madurae.
432644 - Rank order of sarcoma susceptibility among mouse strains reverses with low concentratio...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-7
Journal Detail:
Title:  The Journal of antimicrobial chemotherapy     Volume:  -     ISSN:  1460-2091     ISO Abbreviation:  J. Antimicrob. Chemother.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513617     Medline TA:  J Antimicrob Chemother     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Pharmaceutical and Biomedical Sciences, University of Salerno, 84084 Fisciano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The evolution of RuBisCO stability at the thermal limit of photoautotrophy.
Next Document:  A member of the Ras oncogene family, RAP1A, mediates antileishmanial activity of monastrol.